StockData

Amarin vs Maravai LifeSciences

AMRN and MRVI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMRN and MRVI compare

Amarin is the larger company, worth 2.6 times as much as Maravai LifeSciences ($5.0B against $1.9B).

Maravai LifeSciences grew revenue faster over the last twelve months (−5.0% versus −22.3% for Amarin).

Amarin keeps more of each dollar of sales as profit, with a net margin of −10.9% compared with −37.1% at Maravai LifeSciences.

Amarin scores higher on the StockData Score (10 against 7 for Maravai LifeSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMRNMRVI
Size and price
Market cap$5.0B$1.9B
Share price$11.31$7.40
Change, 1 year−30.5%128%
Change, 5 years−84.5%−82.2%
Beta (5Y)0.730.29
Employees80435
StockData Score
Total score10 (better)7
Valuation score00
Growth score12 (better)
Performance score3 (better)2
Health score6 (better)3
Dividend score00
Valuation
P/S28.4×9.2× (better)
P/B11.3×9.4× (better)
FCF yield–−1.9%
Fair value$7.00$2.74
Margin of safety−61.5% (better)−170%
Growth
Revenue growth (TTM)−22.3%−5.0% (better)
Revenue growth, 5Y average−19.0%−8.1% (better)
Profitability
Gross margin40.9% (better)34.9%
Operating margin−18.2% (better)−56.1%
Net margin−10.9% (better)−37.1%
FCF margin–−17.2%
Return on equity−4.2% (better)−32.9%
Return on invested capital−17.3% (better)−32.4%
Financial health
Debt / equity0.000.72 (better)
Interest coverage–−4.9×
Current ratio3.504.05 (better)
Altman Z-score12.95 (better)4.57
Piotroski F-score7 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions1.0%55.5%
Held by insiders7.0%3.6%
Insider net buying, 12 months–$115K
Short interest, % of float–5.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.